株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:季節性インフルエンザワクチン - 中国における医薬品の予測と市場分析

PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis

発行 GlobalData 商品コード 258674
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:季節性インフルエンザワクチン - 中国における医薬品の予測と市場分析 PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis
出版日: 2012年11月30日 ページ情報: 英文 70 Pages
概要

中国のインフルエンザワクチン市場は、人口の高齢化と、インフルエンザワクチン生産能力の拡大などの要因により、2012年に1億7200万米ドルに達したと推計されています。

当レポートでは、中国の季節性インフルエンザワクチン市場について調査し、市場の概要、競合情勢、主要薬剤の詳細情報とSWOT分析、主要薬剤の売上予測、主要イベントの影響分析、市場影響因子の分析などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状
  • 予後

第4章 疾病管理

  • インフルエンザ予防接種政策
  • 中国
    • ンフルエンザ予防接種の推奨・政策
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合評価
  • 製品プロファイル:主要ブランド

第6章 機会・アンメットニーズ

  • 概要
  • アンメットニーズ
    • 高い患者認識の水準
    • 高齢者・子供(2歳以下)における効能の向上
    • 改善したワクチン副作用のプロファイル
    • より効率的なワクチン製造プロセス
    • よりコスト効果的なワクチン
  • ギャップ分析
  • 機会
    • ウィルス株に対する防御幅の拡大
    • 防御持続期間の増加
    • T細胞の関与

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望薬剤

第8章 市場展望

  • 中国
    • 予測
    • 主なイベント
    • 促進因子・阻害因子

第9章 付録

図表

目次
Product Code: GDHC1019CFR

Summary

GlobalData has released its new Country report, "PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis". Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

The Chinese influenza vaccine market is estimated to be valued at $172m in 2012. Market growth is projected to be driven by the increase of China's elderly population and the growth of its indigenous influenza vaccine production capacity. The barriers to the growth of China's influenza vaccine market include the absence of national vaccination reimbursement program and the country's focus on pandemic/avian influenza.

Scope

  • Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in China from 2012 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the China seasonal influenza market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012 to 2022 in China.

Table of contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis

4. Disease Management

  • 4.1. Influenza Vaccination Policy
  • 4.2. China
    • 4.2.1. Influenza Vaccination Recommendations and Policies
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. FluMist
    • 5.3.2. Afluria
    • 5.3.3. Vaxigrip/Mutagrip
    • 5.3.4. Influvac
    • 5.3.5. Agrippal

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Higher level of patient awareness
    • 6.2.2. Increased efficacy in the elderly and young children (<2 years old)
    • 6.2.3. Improved vaccine side-effect profiles
    • 6.2.4. More efficient vaccine manufacturing process
    • 6.2.5. More cost-effective vaccines
  • 6.3. Gap Analysis
  • 6.4. Opportunities
    • 6.4.1. Expanded breadth of protection against viral strains
    • 6.4.2. Increased duration of protection
    • 6.4.3. T-cell involvement

7. Pipeline Assessment

  • 7.1. Overview

8. Market Outlook

  • 8.1. China
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Vaccine Coverage
    • 9.4.2. Vaccines Included
    • 9.4.3. Key Launch Dates
    • 9.4.4. Influenza Vaccine Tender System Assumptions
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Vaccine Assumptions
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Authors
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Contact Us
  • 9.10. Disclaimer

List of Tables

  • Table 1: Notable Influenza Pandemics
  • Table 2: Symptoms of Influenza
  • Table 3: Influenza Vaccination Recommendation Committees by Country
  • Table 4: Leading Influenza Vaccines, 2012
  • Table 5: Product Profile - FluMist
  • Table 6: FluMist SWOT Analysis, 2012
  • Table 7: Product Profile - Afluria
  • Table 8: Afluria SWOT Analysis, 2012
  • Table 9: Product Profile - Vaxigrip
  • Table 10: Laboratory-Confirmed Influenza Infection Rates in Vaccine or Placebo Recipients and their Household Contacts
  • Table 11: Vaxigrip SWOT Analysis, 2012
  • Table 12: Product Profile - Influvac
  • Table 13: Influvac SWOT Analysis, 2012
  • Table 14: Product Profile - Agrippal
  • Table 15: Agrippal SWOT Analysis, 2012
  • Table 16: Overall Unmet Needs - Current Level of Attainment
  • Table 17: Clinical Unmet Needs - Gap Analysis, 2012
  • Table 18: Sales Forecasts ($m) for Influenza Vaccines in China, 2012-2022
  • Table 19: Key Events Impacting Sales of Influenza Vaccines in China, 2012
  • Table 20: Influenza Vaccine Market - Drivers and Barriers, 2012
  • Table 21: Epidemiology and Market Forecast Chinese Influenza Vaccination Rates (%), 2012-2022
  • Table 22: Key Launch Dates
  • Table 23: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Influenza Virus Structure
  • Figure 2: Sales for Influenza Vaccine in China by Route of administration, 2012-2022
Back to Top